Clinical trial · Interventional
22-G-Procore Needle for the Diagnosis of SETs of the Upper GI Tract
Endoscopic Ultrasound Guided Biopsy of Subepithelial Tumors of the Upper Gastrointestinal Tract Using the 22-G-Procore Needle
NCT01726010CI-TRIAL-00008492PRO-SETunknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this prospective study is to evaluate the feasibility of the 22-G Core Biopsy Needle with reverse bevel (Procore TM) in biopsy sampling of subepithelial tumors of the upper gastrointestinal tract.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Subepithelial Tumors of the Upper Gastrointestinal Tract | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 22-G Procore Needle | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 22-G Procore Needle
- interventionNames
- Device: 22-G Procore Needle
Primary outcomes (1)
- measure
- diagnostic yield
- timeFrame
- 6 months
- description
- Number of patients with adequate tissue sample (which allows definitive diagnosis)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patient age 18 years and older 2. All patients with subepithelial tumors of the upper GI tract (maximum size: 3 cm) Exclusion Criteria: 1. Unable to obtain informed consent 2. ASA class 4 or 5 3. known pregnancy 4. contraindication endoscopy 5. contraindication for taking biopsies
References
Publications (0)
Data not yet available
No reference posted for this study.